Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) entered into a letter of intent with NovoSana (Europe) to potentially acquire up to 75% equity interest in NovoSana (Taicang), a Monday bourse filing said.
Upon completion of the Proposed Transaction, the Target Company will become a holding subsidiary of the Company that will be consolidated into the financial statements of the Group.
The pharmaceutical and chemical products company intends to accelerate its involvement in the fish oil sector through the acquisition.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments